Cardiac transplantation is an effective therapy for endstage heart failure. Because cardiac allograft vasculopathy (CAV) is the major cause of late mortality after heart transplant (HT), there is a need to identify markers that reflect inflammatory or cytotoxic immune mechanisms contributing to its onset. Noninvasive and early stratification of patients at risk remains a challenge for adapting individualized therapy. The CD16 (Fc-gamma receptor 3A [FCGR3A]) receptor was recently identified as a major determinant of antibody-mediated natural killer (NK) cell activation in HT biopsies; however, little is known about the role of CD16 in promoting allograft vasculopathy. This study aimed to investigate whether markers that reflect CD16-dependent circulating NK cell activation may identify patients at higher risk of developing CAV after HT.
H
eart transplant (HT) is a life-saving treatment for patients with advanced heart failure. Predicting the risk of a specific patient developing coronary artery disease in the transplanted heart, also referred to as cardiac allograft vasculopathy (CAV), remains a major issue in the prevention of allograft loss and long-term mortality after HT. [1] [2] [3] In 2016, the International Society for Heart and Lung Transplantation updated the guidelines and risk factors for the development of CAV. 4 The diagnosis of CAV often relies on asymptomatic patients receiving a coronary angiography on a regular basis, which is an invasive procedure that is often performed at stages when lesions have progressed and remain poorly accessible to treatment. The current challenge is to identify noninvasive biomarkers that enable the early stratification of patients at risk 2,5-8 to tailor individualized therapeutic approaches that prevent HT failure. 6, 9 CAV is the result of cumulative endothelial aggression that results from the activation of alloreactive cells. The humoral component is a major determinant of allograft injury after organ transplantation. [10] [11] [12] [13] The inflammatory signals that result from the stimulation of activating Fcreceptors (Fc-Rs) for C-reactive protein serum amyloid P component and immunoglogulin (IgG) expressed on endothelial cells, vascular smooth muscle cells, and monocytes/macrophages are identified as contributors and biomarkers of coronary heart disease pathogenesis. 14 Fc-R polymorphisms have been reported as individual predisposition factors that contribute to vascular disease, 14 notably when the development of cardiovascular disease is associated with auto-or alloimmune disorders and cannot be explained by traditional cardiovascular risk factors. Donor-specific anti-human leukocyte antigen (HLA) circulating antibodies (DSAs) with C1q-binding activity have been associated with a worse prognosis after HT; however, these markers lack the specificity to predict graft outcome in a given patient. 15 In addition to complement-dependent mechanisms, the Fc segment of IgG may stimulate the CD16-dependent cytotoxicity and inflammatory function of immune natural killer (NK) cells, 16, 17 whose critical role has been identified in antibody-driven allograft vasculopathy by using animal models. 18, 19 Recent reports have highlighted the clinical value of tissue-based gene profiling of NK cell transcripts within the heart allograft in the classification of antibodymediated rejection. 20 These approaches have identified a role for the CD16/FcR activation pathway in promoting antibody-mediated vascular damage of heart allograft. 20 A single-nucleotide substitution (rs396991) in the Fcgamma receptor 3A (FCGR3A) gene leads to an allelic variation in amino acid 158 (phenylalanine-F or valine-V) in the IgG binding domain of the CD16 receptor, which impacts the antibody-dependent cell cytotoxic (ADCC) function of NK cells. The FCGR3A-VV polymorphic variant binds with higher affinity to human IgG1 and IgG3 than the FCGR3A-FF variant. The host FCGR3A genotype has been identified as a major determinant of the clinical response to therapeutic IgGs, such as rituximab. 21 In addition, the FCGR3A polymorphisms have been reported to contribute to infection susceptibility [22] [23] [24] and coronary artery diseases 25, 26 and to predispose patients to severe complications after organ transplantation. [27] [28] [29] [30] [31] In the current study, we investigated whether CD16-dependent NK cell activation profiles and FCGR3A polymorphism may be associated with the development of CAV.
METHODS

Patient Population and CAV Grading
We performed a prospective, single-center, observational study that included 103 heart transplant recipients (HTRs) undergoing
Clinical Perspective
What Is New?
• We used a noninvasive NK (natural killer) cell-cellular humoral activation test to evaluate the association between genetic and phenotypic markers of the CD16-dependent NK cell activation pathway and development of cardiac allograft vasculopathy.
• We report that the FCGR3A-VV polymorphic variant, which encodes the highly responsive CD16 Fcreceptor, was identified as an independent baseline predictor of cardiac allograft vasculopathy and may be useful for stratifying patients at higher risk of rejection.
• This study identifies a potential immune mechanism underlying the interindividual variability of the recipient's complement-independent humoral response that relies on its FCGR3A genotype and CD16-dependent NK cell activation profile.
What Are the Clinical Implications?
• Noninvasive profiling of the FCGR3A polymorphism and CD16-dependent NK cell responses may warrant personalized monitoring of heart transplant outcomes.
• NK cell-cellular humoral activation test appraisal of risk may potentially limit the recommendation of invasive biopsies to sensitized patients with high humoral responsiveness.
• Indexing of patient-to-patient variability regarding NK cell responses may be of value in defining potency markers that anticipate the response to rituximab or intravenous immunoglobulin treatment of antibody-mediated rejection.
• The recognition of CD16 as a major checkpoint that controls immune surveillance may promote the possibility of using NK cell-targeted therapies to limit vascular damage in patients identified as being at high humoral risk. 
Cells, Plasma, and Sera
Cell and sera samples of HTRs and healthy donors were collected from Assistance Publique Hopitaux de Marseille and Etablissement Français du Sang, respectively. Peripheral blood mononuclear cells (PBMCs) were isolated from HTR and healthy donor blood samples by using Ficoll gradients.
Anti-HLA Antibody Detection
Sera from all patients were tested for anti-HLA antibodies by using multianalyte bead assays performed on a Luminex-based LABScan 200 flow analyzer. The antibody specificity and binding levels (mean fluorescence intensity [MFI] ) were determined by the LABScreen Single Antigen bead assay (One Lambda, Thermo Fisher Scientific) and analyzed with HLA Fusion software. The binding reactivity was considered saturated with an MFI >15 000, positive with a MFI>500 to 10 000 or negative with an MFI<500. The HLA antibody specificities were analyzed in reference to the HLA typing of donors to identify DSA.
C1q Detection
The C1qScreen assay was used to test the capacity of DSA to bind C1q (One Lambda, Part of ThermoFisher Scientific). The C1q complement component bound by the antigen-antibody complex was detected with an R-PE-labeled anti-C1q antibody. The fluorescence intensity was measured using a Luminex-based LABScan 200 flow analyzer. MFI>1000 for the C1qScreen assay was considered positive.
FCGR3A Genotyping
The detection of FCGR3A (F158V/rs396991) polymorphisms was performed by using the SNAPSHOT technique. Data were analyzed using GeneMapper 4.0 and the GeneRate computer tool package. 32 For each of the different alleles obtained, both strands of the polymerase chain reaction products were sequenced using the BigDye Terminator v1. + NK cell subset. At least 3000 events were analyzed in the NK lymphocyte gate using a Navios cytometer (Beckman Coulter).
Phenotypic Analysis of AntibodyDependent NK Cell Activation
The NK cell-cellular humoral activation test (NK-CHAT) analysis was performed as previously described. 16 In brief, effector PBMCs and 500 000 target cells (CD20 + B-EBV-transformed or K562 cell lines) were incubated with 10% fetal calf serum for 3 hours at 37°C using a 1:1 effector/target ratio in the presence of Golgi Stop and CD107a-PC5 antibodies (Becton Dickinson). Cells were washed and labeled with CD3-ECD, CD16-PE, and CD56-PC7 antibodies (Beckman Coulter) for 15 minutes at room temperature. Data acquisition was performed on a Navios cytometer. CD107a/Lamp1 expression patterns were analyzed in the CD3 -
CD56
+ NK subset gated within the PBMCs. Analysis of the K562-induced NK cell expression of CD107a/ Lamp1 cytotoxic granule exocytosis enabled the evaluation of the natural cytotoxic activity of NK cells. The NK-ADCC activity was evaluated after the addition of 10 γ/mL rituximab to the PBMC-B cell target coculture for 3 hours by measuring the percentage of CD107a/Lamp1-positive CD3 -CD56 + NK cells. The level of CD16 engagement was quantified as the ratio between the MFI of NK cell CD16 expression (CD16MFI) observed when PBMCs were incubated with CD20 + B-cell targets in the presence or absence of rituximab. The level of rituximab-induced NK cell CD16 engagement was defined as the CD16 downregulation index (CD16DRI).
Statistical Analysis
Statistical analysis was performed using Graph Pad Prism 5 software (GraphPad Software) and IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp). Quantitative variables were summarized as means±SDs or medians and interquartile ranges. Continuous variables were compared by using the Student t test or the nonparametric Mann-Whitney test. Oneway analysis of variance was used to compare >2 groups. The association between continuous variables was analyzed using the Spearman or Pearson rank correlation analysis. Categorical variables were reported as counts or percentages and compared using a χ 2 or Fisher exact test. A P value<0.05
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was considered to represent a statistically significant difference. The time of first CAV diagnosis was compared across the FCGR3A genotypes with the use of Kaplan-Meier estimation combined with the log-rank test. The associations between CAV and clinical, demographic, and immunologic variables were assessed using a univariate analysis. Variables identified as significantly associated with CAV (P<0.05, Table 1 ) enabled the construction of logistic regression multivariate models used to calculate adjusted tests that characterized the risk factors associated with CAV.
RESULTS
Clinical Characteristics of HTRs
The characteristics of the study cohort are shown in Ta -group. The rates of CAV tended to be higher when a female recipient received a heart from a male donor (n=13 CAV + of 20 patients, P=0.161) or when the patient had signs of hypertension before transplant (P=0.071). Renal dysfunction at the time of enrollment (estimated glomerular filtration rate <60 mL·min -1 ·1.73 m -2 ) was significantly associated with CAV ( Table 1) .
The maintenance immunosuppressant mainly consisted of a tritherapy regimen that combined CNIs, mycophenolate mofetil, and steroids (group A, n=68), which was associated with a lower CAV incidence (Table 1); everolimus, CNI, and steroids (group B, n=15); or bi-or monotherapy (group C, steroid or mycophenolate mofetil withdrawal, n=18; CNI monotherapy, n=2). Posttransplant infections (viral, fungal, bacterial, or parasitic) were observed in 48 patients (30 and NK peripheral blood cell counts were preserved in HTRs and exhibited values that were comparable to the reference values observed in a cohort of healthy controls. In contrast, B-and CD4
+ T-lymphocyte cell counts were significantly lower in the HTRs than those in the healthy controls. No significant difference was identified in the distribution of lymphocyte cell subsets between the CAV + and CAV -groups ( Figure I in the online-only Data Supplement).
NK Cell Cytotoxic Activity Is Preserved in HTRs
Flow cytometry analysis of the membrane expression of the cytotoxic granule CD107a/Lamp1 NK cell marker indicated that constitutive NK cell activation (percentage of CD107a/Lamp1-positive NK cells in the absence of target stimulation) and K562-driven natural cytotoxicity of NK cells were comparable in the HTR and control groups ( Figure 1A) . Quantification of the antibody-dependent cytotoxic activity of peripheral NK cells toward autologous B lymphocytes challenged with rituximab (NK-ADCC) indicated a high interindividual heterogeneity among the HTRs ( Figure 1A) . The NK-ADCC intensity was correlated with the number of autologous circulating B lymphocytes that expressed the CD20 target antigen ( Figure 1B 
FCGR3A Polymorphism Is Associated With the Level of CD16-Dependent NK Cell Activation
The CD16DRI was also significantly associated with the constitutive CD16 expression on circulating NK cells (CD16MFI; Figure 2A) .
We subsequently investigated whether this interindividual NK-ADCC variation may relate to polymorphic variations in the FCGR3A gene that encodes CD16. We showed that CD16DRI was associated with the FC-GR3A genotype of HTRs and was higher in the patients with homozygous FCGR3A-VV than that in the HTRs bearing the FCGR3A-VF or FCGR3A-FF genotype (Figure 2B) . Similarly, we confirmed that the basal level of CD16 expression (CD16MFI) in circulating NK cells was significantly higher in the recipients bearing the homozygous FCGR3A-VV genotype ( Figure 2C ).
FCGR3A-VV Genotype Is an Independent Predictor of CAV
The frequency of the FCGR3A-VV genotype was significantly higher in the CAV + group (odds ratio, 3.9; 95% confidence interval, 1.18-12.99; P=0.0317; positive predictive value=0.92, negative predictive value=0.25) than that in the CAV-free or healthy control groups (P=0.03; Figure 3A) . A Kaplan-Meier analysis adjusted for the time posttransplant at first CAV diagnosis confirmed that the median CAV-free survival was 5 years in the FCGR3A-VV HTRs, whereas the individuals who bear the FF/VF genotype had a median CAV-free survival of 9 years post-HT ( Figure 3B ). The FCGR3A-VV genotype was also associated with a higher incidence of posttransplant viral infections (P=0.005; odds ratio, 4.92; 95% confidence interval, 1.6-15.1), whereas the FCGR3A-FF genotype (35 patients) was associated with ), and an enhanced frequency of circulating DSAs with MFI>10 000 or C1q-binding activity (P=0.037) ( Table I in the online-only Data Supplement). A majority of the patients who developed CMV infection also developed CAV. Fourteen of the 18 patients who developed CMV infection after HT had a diagnosis of CAV (3 grade 3, 1 grade 2, and 10 grade 1). It is noteworthy that 50% of these patients who developed CMV and CAV were FCGR3A-VV, whereas none of the patients who developed CMV infection in the absence of CAV exhibited this FCGR3A-VV susceptibility genotype (Tables II and III in the onlineonly Data Supplement) .
We further challenged the independent value of these markers of the CD16 NK cell activation pathway as susceptibility markers for CAV using regression multivariate analysis models that introduced confounding factors identified in the univariate analysis (Table 1) . We identified an elevated risk of developing CAV in FCGR3A-VV (Table 2) , independent of other CAV risk factors, such as time since transplantation, donor age, recipient age and body mass index, occurrence of posttransplant viral and bacterial infections, chronic kidney disease, and immunosuppressive regimen. We further characterized the risk associated with the FCGR3A genotype at the time of transplant by constructing a predictive multivariate model that restricted the adjusting variables to pretransplant features. The FCGR3A-VV genotype remained a strong predictor of CAV development independent of other risk factors, such as donor age, hypertension, and male donor to female recipient status (Table 3) . High constitutive NK cell surface expression of CD16 (Table IV in 
DISCUSSION
Because CAV is a major cause of late mortality after HT, there is an urge to identify early noninvasive markers that reflect immune mechanisms contributing to its onset. Noninvasive early stratification of patients at risk is also a major challenge that favors the personalized indication of treatment. The potential contribution of genetic variation conditioning inflammatory processes that result from C-reactive protein ligation to Fc-R has been evoked as a mechanism promoting vascular injury and predisposition to cardiovascular disease. Targeted anti-inflammatory therapies have been proposed as novel approaches to reduce cardiovascular risk. 33 Our study is the first investigation to establish a link between the genetic variation in the FCGR3A/CD16 activating Fc-R and the predisposition for heart vasculopathy. Recent reports have identified the Fc-R CD16 as a major checkpoint that controls inflammatory and vascular cytotoxicity resulting from immune alloreactivity. Our observations come on the heels of the recent evaluation of intragraft mRNA transcripts that suggests that CD16-dependent NK activation pathways are prominent for the development of antibody-mediated rejection after heart transplantation. 20 These findings illustrate the clinical potential of the biopsy measurement of CD16 and NK cell transcripts to refine the classification and diagnosis of antibody-mediated rejection. Our results further point to an underlying mechanism associating this CD16 NK cell pathway along with the FCGR3A-VV polymorphism with the development of CAV. We further identify noninvasive biomarkers that reflect the intrinsic potential of a given recipient to mount deleterious CD16-dependent cytotoxic immune responses toward the heart vasculature. The strength 
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of our study is to provide evidence that the FCGR3A-VV genetic variant that encodes the CD16 receptor with high affinity for the Fc portion of antibodies is associated with an enhanced CD16-driven NK cell activation potential and behaves as a susceptibility factor to identify patients at a higher risk of developing coronary artery disease of the transplanted heart. At the individual level, a highly responsive NK cell profile associated with the VV genotype and CD16 expression levels is expected to shape the intensity of NK cell antibody-dependent cellular cytotoxic and inflammatory paracrine function through the release of CD107a/Lamp1 cytotoxic granules and inflammatory cytokines, such as interferon-γ. We show that, despite immunosuppression, the number and cytotoxic function of circulating immune NK cells are maintained in HTRs and exhibit high patient-to-patient variability. Although preservation of this immune potential may be beneficial for thwarting the neoplastic and infectious complications that often arise in immunosuppressed HTRs, it may cause adverse effects of auto-or alloantibodies toward graft endothelium in immunized patients who bear the high-affinity FCGR3A-VV allele. The phenotypic NK-CHAT evaluation of peripheral blood NK cell activation in a relevant cohort of HTRs showed that patients developing posttransplant CAV predominantly exhibit the highest CD16 expression and CD16-dependent NK cell activation potential in response to antibodies. We show that the intensity of the NK cell response to rituximab depends not only on the number of HTR peripheral B cells that express the CD20 antigen, but also on the intrinsic level of CD16 expression of the recipient, which is, in part, conditioned by the FCGR3A-VV genotype.
As previously described, we showed that a majority of patients who developed CMV infection also developed CAV, suggesting that CMV was highly associated with the development of CAV in the study cohort. It is interesting that we also observed that, in comparison with the FCGR3A-FF/VF genotype, the FCGR3A-VV polymorphism appeared to contribute to increased susceptibility to CMV infection. It is of note that 50% of these patients who developed CMV and CAV (CMV + CAV + ) were FCGR3A-VV, whereas none of the patients who developed CMV infection in the absence of CAV exhibited this FCGR3A-VV susceptibility genotype. These data provide a mechanistic link between the CD16 signaling pathway and the highly variable capacity of a given recipient to trigger immune activation in response to a viral or humoral challenge, both identified as risk factors of CAV.
As previously reported, a history of persistent chronic kidney disease (estimated glomerular filtration rate <60) evaluated in transplant recipients before HT and at the time of study enrollment was identified as an independent risk factor for CAV. The pathological cross talk between heart and kidney organ dysfunction, also referred to as the cardiorenal syndrome, is widely recognized. Various factors participate in the alteration of renal function in HTRs, both before and after HT. Although the multivariable analysis retained kidney dysfunction before graft, recipient age, and percent left ventricular ejection fraction as independent risk factors associated with chronic kidney disease (estimated glomerular filtration rate <60), no significant association was identified between renal dysfunction and CNI dosage or CD16-dependent NK cell activation.
The strength of the study is to provide evidence that the identification of the CD16 profile of the recipient as a risk factor associated with the development of CAV is, in part, independent of other risk factors associated with the cardiorenal syndrome, such as donor/recipient age, uremic or infectious status, and immunosuppressive regimen.
Genotyping of the FCGR3A polymorphic variant would be easy to implement in the pretransplant setting; therefore, we challenge the view that this susceptibility marker may represent an independent predictor with potential value in the identification of patients at higher risk of developing CAV. Previous studies have reported associations between FCGR polymorphisms and adverse infectious events or accelerated atherosclerosis after organ transplant 27, 29, 30 ; however, the link between the FC-GR3A single-nucleotide polymorphism and infection has not been elucidated in the context of HT. A recent study reported that patients with a combined FCGR2A-131H/H and FCGR3A-FF (low IgG-binding affinity) genotype were more susceptible to blood-borne infections and exhibited increased mortality after liver transplant. Previous studies have identified CMV infection as a risk factor associated with the development of allograft vascular lesions. 34, 35 In the present cohort, the FCGR3A-VV genotype was identified as a risk factor associated with viral infections. We provide evidence that the FCGR3A-VV genotype is associated with an increased susceptibility to CAV independent of the pretransplant recipient and donor CMV combination, posttransplant infectious status, or immunosuppressive regimen. This finding suggests that, on CMV infectious challenge, FCGR3A-VV HTRs may develop more potent humoral inflammatory responses that favor the development of allograft vasculopathy.
It is interesting to note that the association of CAV with the genetic and functional biomarkers of the CD16 activation pathway was independent of the DSA C1q-binding activity. Thus, our study indicates a potential role for the FCGR3A-VV single-nucleotide polymorphism as a susceptibility factor that controls the chronic cytotoxicity of antibodies independent of the complement pathway. Although this association remains unclear, enhanced MFI and C1q-binding activity of DSAs and skin cancer rates were associated with the FCGR3A-FF genotype, which thus suggests that the threshold of innate immune NK cell immunosurveillance may be lowered in these HTRs. It is interesting to note that, among the 8 patients who exhibited the highest levels of circulating DSA (MFI>15 000), all 4 patients who remained CAV free at the time of enrollment had the FCGR3A-FF lowresponsive genotype. As shown in the kidney transplant setting, 28 we suggest that a noninvasive NK-CHAT evaluation of CD16-mediated reactivity may reveal features of underlying humoral mechanisms that involve NK cell chronic activation toward the donor heart that may not be fully appreciated from a conventional Luminex assessment of HLA circulating antibodies. We expect that the noninvasive CD16DRI evaluation of recipient NK cell reactivity toward donor cells may indicate the pathogenic activity of antiendothelial antibodies that remains undetectable with conventional assays and exhibits a high potential to promote vasculopathy in high responders with the FCGR3A-VV genotype.
Our work has several limitations. First, the FCGR3A profiles were only analyzed in 103 HTRs, and the ability of the NK-CHAT to predict CAV must be further demonstrated in larger prospective and multicentric cohorts of HTRs with defined pre-and posttransplant time points. Nevertheless, given the multiple risk factors evaluated, none of the other Fc-R polymorphisms evaluated was significantly associated with CAV in the present cohort. Considering this primary analysis, we also need to challenge the predictive value of these CD16-dependent NK cell activation indexes evaluated at the time of transplant with more stringent end points, such as graft failure, cancer, and viral immune surveillance, 
antibody-mediated rejection, and patient mortality. FcγRs are also expressed on neutrophils and monocyte/ macrophage subsets; another limitation of our study is that we only focused on the implication of CD16 in NK cell immune cytotoxic activation.
Our study provides evidence of a role for NK immune cells as effectors of cardiac allograft dysfunction. Because CD16 is a major component that controls complex IgG-mediated effector functions of immune cells in response to alloimmune, neoplastic, and infectious challenges, we expect that this genetic and phenotypic assessment of CD16/FCGR3A may provide biomarkers that reflect the complexity of immune mechanisms associated with heart allograft loss.
In addition, as shown in the kidney transplant setting, 16 the noninvasive assay NK-CHAT monitoring of Fc-R and antibody-dependent NK cell alloreactivity may be a valuable tool to identify patients at higher risk of developing CAV after HT. The indexing of patient-topatient variability regarding NK cell responses also suggests that NK-CHAT may be of value in defining potency markers that anticipate response to therapy, notably in the rituximab or intravenous immunoglobulin treatment of antibody-mediated rejection.
CONCLUSION
Our study unravels the relevance of the CD16 axis in controlling the intensity of IgG-mediated NK cell cytotoxic activation in HTRs. Our work suggests that individualized scoring of the recipient's intrinsic capacity to elicit CD16-dependent NK cell activation may provide an integrated view of the interplay between susceptibility single-nucleotide polymorphisms, humoral innate cell alloreactivity, and CMV in the promotion of coronary artery disease in the transplanted heart. This indexing of patient-to-patient variability regarding NK cell responses may be of value in defining noninvasive biomarkers that anticipate CAV risk and response to therapy. Translated to a simplified test, the analysis of the FCGR3A polymorphism and NK-ADCC activation potential may warrant informative noninvasive monitoring of HT outcomes both before and after transplant. An appraisal of the risk may potentially limit the recommendation of invasive biopsies to a subset of immunized patients with high ADCC responsiveness, whereas less stringent monitoring may be considered in patients with a lower ADCC reactive potential. This method may also provide novel tools to quantify the individual benefit/risk profile of the patient to adapt immunosuppressive therapies. The recognition of CD16 as a major checkpoint that controls immune surveillance in the setting of HT may promote the possibility of designing and testing novel individualized NK cell-targeted therapies to limit vascular damage in sensitized patients identified as being at high humoral risk. 
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